NasdaqCM - Nasdaq Real Time Price USD

Exact Sciences Corporation (EXAS)

Compare

56.50

-0.18

(-0.32%)

At close: January 10 at 4:00:02 PM EST

56.50

0.00

(0.00%)

After hours: January 10 at 4:42:13 PM EST

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

MADISON, Wis., January 13, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ended December 31, 2024.

Business Wire 6 hours ago

EXAS
-0.32%
Should Exact Sciences Stock Stay in Your Portfolio Right Now?

EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.

Zacks 4 days ago

EXAS
-0.32%
HAE
Exact Sciences price target raised to $70 from $60 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – t

TipRanks 9 days ago

EXAS
-0.32%
Exact Sciences to Participate in J.P. Morgan Healthcare Conference

MADISON, Wis., January 02, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

Business Wire 10 days ago

EXAS
-0.32%
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

MIRM

EXAS
-0.32%
Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

EXAS
-0.32%
Exploring High Growth Tech Stocks in December 2024

Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions.

Simply Wall St. last month

EXAS
-0.32%
VERX

NTNX
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

Editor’s note: The headline of this story was updated to correct an error related to the reported day of the week. On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule. Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes that the determinations effectively raise reimbursem

Benzinga last month

EXAS
-0.32%
Exact Sciences to Participate in December Investor Conferences

MADISON, Wis., November 26, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.

Business Wire last month

EXAS
-0.32%
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

MADISON, Wis., November 25, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas.

Business Wire last month

EXAS
-0.32%
Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics […]

Insider Monkey last month

EXAS
-0.32%
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test

Exact Sciences presents new positive evidence backing the development of an MCED test.

Zacks last month

EXAS
-0.32%
GMED

HAE
Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock

Those following along with Exact Sciences Corporation ( NASDAQ:EXAS ) will no doubt be intrigued by the recent purchase...

Simply Wall St. last month

EXAS
-0.32%
Exact Sciences showcases early cancer detection test data at AACR meeting

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung cancer.

Clinical Trials Arena last month

EXAS
-0.32%
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

MADISON, Wis., November 13, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening

Business Wire last month

EXAS
-0.32%
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund returned 9.15% while the benchmark, the Russell 2500 Growth Index, returned 6.99%. A strong market rally occurred throughout the quarter, and the Columbia Acorn Fund beat its benchmark […]

Insider Monkey 2 months ago

EXAS
-0.32%
Exact Sciences’ forecast cut shocks analysts

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.

MedTech Dive 2 months ago

EXAS
-0.32%
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investor's Business Daily 2 months ago

GH
+0.31%
EXAS
-0.32%
Exact Sciences Third Quarter 2024 Earnings: Misses Expectations

Exact Sciences ( NASDAQ:EXAS ) Third Quarter 2024 Results Key Financial Results Revenue: US$708.7m (up 13% from 3Q...

Simply Wall St. 2 months ago

EXAS
-0.32%
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook.

Investor's Business Daily 2 months ago

EXAS
-0.32%

Performance Overview

Return	EXAS	S&P 500
YTD	+0.53%	-1.35%
1-Year	-18.80%	+22.51%
3-Year	-25.32%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Exact Sciences Corporation (EXAS)

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

Should Exact Sciences Stock Stay in Your Portfolio Right Now?

Exact Sciences price target raised to $70 from $60 at Evercore ISI

Exact Sciences to Participate in J.P. Morgan Healthcare Conference

Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?

Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?

Exploring High Growth Tech Stocks in December 2024

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED)

Exact Sciences to Participate in December Investor Conferences

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test

Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock

Exact Sciences showcases early cancer detection test data at AACR meeting

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy

Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter

Exact Sciences’ forecast cut shocks analysts

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Exact Sciences Third Quarter 2024 Earnings: Misses Expectations

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

Performance Overview